Finch Therapeutics Group Inc (FNCH)
2.36
-0.13
(-5.22%)
USD |
NASDAQ |
May 03, 16:00
2.36
0.00 (0.00%)
After-Hours: 16:09
Finch Therapeutics Group Cash from Operations (TTM): -31.50M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -31.50M |
September 30, 2023 | -42.07M |
June 30, 2023 | -55.90M |
March 31, 2023 | -62.59M |
December 31, 2022 | -74.85M |
September 30, 2022 | -74.37M |
June 30, 2022 | -69.62M |
Date | Value |
---|---|
March 31, 2022 | -77.56M |
December 31, 2021 | -67.13M |
September 30, 2021 | -63.63M |
June 30, 2021 | -56.19M |
March 31, 2021 | -40.57M |
December 31, 2020 | -31.33M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-77.56M
Minimum
Mar 2022
-31.33M
Maximum
Dec 2020
-57.49M
Average
-62.59M
Median
Mar 2023
Cash from Operations (TTM) Benchmarks
ACADIA Pharmaceuticals Inc | 16.70M |
Vanda Pharmaceuticals Inc | 12.80M |
Sage Therapeutics Inc | -424.74M |
BioSig Technologies Inc | -17.31M |
Palisade Bio Inc | -11.13M |